|
Breast Carcinoma
|
|
0.740 |
GeneticVariation
|
BEFREE |
Compared to never users of MHT with the rs865686 GG genotype, the association between current MHT use and breast cancer risk for the TT genotype (OR 1.79, 95 % CI 1.43-2.24; P interaction = 1.2 × 10(-4)) was less than expected on the multiplicative scale.
|
26802016 |
2016 |
|
Malignant neoplasm of breast
|
|
0.740 |
GeneticVariation
|
BEFREE |
Compared to never users of MHT with the rs865686 GG genotype, the association between current MHT use and breast cancer risk for the TT genotype (OR 1.79, 95 % CI 1.43-2.24; P interaction = 1.2 × 10(-4)) was less than expected on the multiplicative scale.
|
26802016 |
2016 |
|
Breast Carcinoma
|
|
0.740 |
GeneticVariation
|
GWASCAT |
Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer.
|
25751625 |
2015 |
|
Malignant neoplasm of breast
|
|
0.740 |
GeneticVariation
|
GWASDB |
Large-scale genotyping identifies 41 new loci associated with breast cancer risk.
|
23535729 |
2013 |
|
Breast Carcinoma
|
|
0.740 |
GeneticVariation
|
GWASCAT |
Large-scale genotyping identifies 41 new loci associated with breast cancer risk.
|
23535729 |
2013 |
|
Malignant neoplasm of breast
|
|
0.740 |
GeneticVariation
|
BEFREE |
This study is the first to show that rs865686 is a susceptibility marker for ER(+) breast cancer.
|
22859399 |
2012 |
|
Malignant neoplasm of breast
|
|
0.740 |
GeneticVariation
|
BEFREE |
Recent genome-wide association studies of breast cancer have identified eight additional breast cancer susceptibility loci: rs1011970 (9p21, CDKN2A/B), rs10995190 (ZNF365), rs704010 (ZMIZ1), rs2380205 (10p15), rs614367 (11q13), rs1292011 (12q24), rs10771399 (12p11 near PTHLH) and rs865686 (9q31.2).
|
22348646 |
2012 |
|
Breast Carcinoma
|
|
0.740 |
GeneticVariation
|
BEFREE |
Recent genome-wide association studies of breast cancer have identified eight additional breast cancer susceptibility loci: rs1011970 (9p21, CDKN2A/B), rs10995190 (ZNF365), rs704010 (ZMIZ1), rs2380205 (10p15), rs614367 (11q13), rs1292011 (12q24), rs10771399 (12p11 near PTHLH) and rs865686 (9q31.2).
|
22348646 |
2012 |
|
Breast Carcinoma
|
|
0.740 |
GeneticVariation
|
BEFREE |
This study is the first to show that rs865686 is a susceptibility marker for ER(+) breast cancer.
|
22859399 |
2012 |
|
Malignant neoplasm of breast
|
|
0.740 |
GeneticVariation
|
GWASDB |
We identified a novel risk locus for breast cancer at 9q31.2 (rs865686: OR = 0.89, 95% CI = 0.85 to 0.92, P = 1.75 × 10(-10)).
|
21263130 |
2011 |
|
Malignant neoplasm of breast
|
|
0.740 |
GeneticVariation
|
BEFREE |
We identified a novel risk locus for breast cancer at 9q31.2 (rs865686: OR = 0.89, 95% CI = 0.85 to 0.92, P = 1.75 × 10(-10)).
|
21263130 |
2011 |
|
Breast Carcinoma
|
|
0.740 |
GeneticVariation
|
GWASCAT |
We identified a novel risk locus for breast cancer at 9q31.2 (rs865686: OR = 0.89, 95% CI = 0.85 to 0.92, P = 1.75 × 10(-10)).
|
21263130 |
2011 |
|
Breast Carcinoma
|
|
0.740 |
GeneticVariation
|
BEFREE |
We identified a novel risk locus for breast cancer at 9q31.2 (rs865686: OR = 0.89, 95% CI = 0.85 to 0.92, P = 1.75 × 10(-10)).
|
21263130 |
2011 |
|
Oestrogen receptor positive breast cancer
|
|
0.020 |
GeneticVariation
|
BEFREE |
We recently identified a novel susceptibility variant, rs865686, for estrogen-receptor positive breast cancer at 9q31.2.
|
25652398 |
2015 |
|
Oestrogen receptor positive breast cancer
|
|
0.020 |
GeneticVariation
|
BEFREE |
9q31.2-rs865686 as a susceptibility locus for estrogen receptor-positive breast cancer: evidence from the Breast Cancer Association Consortium.
|
22859399 |
2012 |
|
estrogen receptor-negative breast cancer
|
|
0.010 |
GeneticVariation
|
BEFREE |
Four SNPs were associated with the risk of breast cancer for BRCA2 mutation carriers: rs10995190, P-trend = 0.015; rs1011970, P-trend = 0.048; rs865686, 2df-P = 0.007; rs1292011 2df-P = 0.03. rs10771399 (PTHLH) was predominantly associated with estrogen receptor (ER)-negative breast cancer for BRCA1 mutation carriers (HR = 0.81, 95% CI: 0.74 to 0.90, P-trend = 4 × 10-5) and there was marginal evidence of association with ER-negative breast cancer for BRCA2 mutation carriers (HR = 0.78, 95% CI: 0.62 to 1.00, P-trend = 0.049).
|
22348646 |
2012 |